Cargando…

Photonic Technology for In Vivo Monitoring of Hypoxia–Ischemia

Surveillance of physiological parameters of newborns during delivery triggers medical decision‐making, can rescue life and health, and helps avoid unnecessary cesareans. Here, the development of a photonic technology for monitoring perinatal asphyxia is presented and validated in vivo in a preclinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Olaetxea, Ion, Lafuente, Hector, Lopez, Eneko, Izeta, Ander, Jaunarena, Ibon, Seifert, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811478/
https://www.ncbi.nlm.nih.gov/pubmed/36377426
http://dx.doi.org/10.1002/advs.202204834
_version_ 1784863542478897152
author Olaetxea, Ion
Lafuente, Hector
Lopez, Eneko
Izeta, Ander
Jaunarena, Ibon
Seifert, Andreas
author_facet Olaetxea, Ion
Lafuente, Hector
Lopez, Eneko
Izeta, Ander
Jaunarena, Ibon
Seifert, Andreas
author_sort Olaetxea, Ion
collection PubMed
description Surveillance of physiological parameters of newborns during delivery triggers medical decision‐making, can rescue life and health, and helps avoid unnecessary cesareans. Here, the development of a photonic technology for monitoring perinatal asphyxia is presented and validated in vivo in a preclinical stage. Contrary to state of the art, the technology provides continuous data in real‐time in a non‐invasive manner. Moreover, the technology does not rely on a single parameter as pH or lactate, instead monitors changes of the entirety of physiological parameters accessible by Raman spectroscopy. By a fiber‐coupled Raman probe that is in controlled contact with the skin of the subject, near‐infrared Raman spectra are measured and analyzed by machine learning algorithms to develop classification models. As a performance benchmarking, various hybrid and non‐hybrid classifiers are tested. In an asphyxia model in newborn pigs, more than 1000 Raman spectra are acquired at three different clinical phases—basal condition, hypoxia–ischemia, and post‐hypoxia–ischemia stage. In this preclinical proof‐of‐concept study, figures of merit reach 90% levels for classifying the clinical phases and demonstrate the power of the technology as an innovative medical tool for diagnosing a perinatal adverse outcome.
format Online
Article
Text
id pubmed-9811478
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98114782023-01-05 Photonic Technology for In Vivo Monitoring of Hypoxia–Ischemia Olaetxea, Ion Lafuente, Hector Lopez, Eneko Izeta, Ander Jaunarena, Ibon Seifert, Andreas Adv Sci (Weinh) Research Articles Surveillance of physiological parameters of newborns during delivery triggers medical decision‐making, can rescue life and health, and helps avoid unnecessary cesareans. Here, the development of a photonic technology for monitoring perinatal asphyxia is presented and validated in vivo in a preclinical stage. Contrary to state of the art, the technology provides continuous data in real‐time in a non‐invasive manner. Moreover, the technology does not rely on a single parameter as pH or lactate, instead monitors changes of the entirety of physiological parameters accessible by Raman spectroscopy. By a fiber‐coupled Raman probe that is in controlled contact with the skin of the subject, near‐infrared Raman spectra are measured and analyzed by machine learning algorithms to develop classification models. As a performance benchmarking, various hybrid and non‐hybrid classifiers are tested. In an asphyxia model in newborn pigs, more than 1000 Raman spectra are acquired at three different clinical phases—basal condition, hypoxia–ischemia, and post‐hypoxia–ischemia stage. In this preclinical proof‐of‐concept study, figures of merit reach 90% levels for classifying the clinical phases and demonstrate the power of the technology as an innovative medical tool for diagnosing a perinatal adverse outcome. John Wiley and Sons Inc. 2022-11-15 /pmc/articles/PMC9811478/ /pubmed/36377426 http://dx.doi.org/10.1002/advs.202204834 Text en © 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Olaetxea, Ion
Lafuente, Hector
Lopez, Eneko
Izeta, Ander
Jaunarena, Ibon
Seifert, Andreas
Photonic Technology for In Vivo Monitoring of Hypoxia–Ischemia
title Photonic Technology for In Vivo Monitoring of Hypoxia–Ischemia
title_full Photonic Technology for In Vivo Monitoring of Hypoxia–Ischemia
title_fullStr Photonic Technology for In Vivo Monitoring of Hypoxia–Ischemia
title_full_unstemmed Photonic Technology for In Vivo Monitoring of Hypoxia–Ischemia
title_short Photonic Technology for In Vivo Monitoring of Hypoxia–Ischemia
title_sort photonic technology for in vivo monitoring of hypoxia–ischemia
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811478/
https://www.ncbi.nlm.nih.gov/pubmed/36377426
http://dx.doi.org/10.1002/advs.202204834
work_keys_str_mv AT olaetxeaion photonictechnologyforinvivomonitoringofhypoxiaischemia
AT lafuentehector photonictechnologyforinvivomonitoringofhypoxiaischemia
AT lopezeneko photonictechnologyforinvivomonitoringofhypoxiaischemia
AT izetaander photonictechnologyforinvivomonitoringofhypoxiaischemia
AT jaunarenaibon photonictechnologyforinvivomonitoringofhypoxiaischemia
AT seifertandreas photonictechnologyforinvivomonitoringofhypoxiaischemia